FDA approves AREXVY (GSK) for use in individuals aged 50-59 at increased risk for lower respiratory tract disease caused by RSV.
Immunization Coalition of Delaware
Immunization is one of the most effective public health prevention strategies!
FDA approves AREXVY (GSK) for use in individuals aged 50-59 at increased risk for lower respiratory tract disease caused by RSV.